AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9615361 — intervention group
Group type: COMPARATOR
Intervention: Healthy adolescent girls (control group)
Number of subjects: 146
Study 8594399 — intervention group
Group type: EXPERIMENTAL
Intervention: Read-write tutorial version
Number of subjects: 0
Study 8594399 — intervention group
Group type: COMPARATOR
Intervention: Read-only tutorial version
Number of subjects: 0
Study 8594399 — intervention group
Group type: EXPERIMENTAL
Intervention: Both software versions (read-only and read-write)
Number of subjects: 0
Study 2642440 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 5 mg/kg CDC plus 5 mg/kg UDC
Number of subjects: 120
Study 2642440 — intervention group
Group type: COMPARATOR
Intervention: UDC alone (10 mg/kg)
Number of subjects: 120
Study 4850208 — intervention group
Group type: EXPERIMENTAL
Intervention: Truncal vagotomy and drainage (V-D)
Number of subjects: 200
Study 4850208 — intervention group
Group type: EXPERIMENTAL
Intervention: Truncal vagotomy and antrectomy (V-R)
Number of subjects: 200
Study 30790028 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative care-led meetings
Number of subjects: 306
Study 30790028 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative perception of patient’s physical comfort and emotional support
Number of subjects: 306
Study 30790028 — intervention group
Group type: EXPERIMENTAL
Intervention: Surrogate perception that clinicians did not listen to concerns
Number of subjects: 306
Study 30790028 — intervention group
Group type: EXPERIMENTAL
Intervention: Failure of the physician to explain how the patient’s pain would be treated
Number of subjects: 306
Study 30790028 — intervention group
Group type: EXPERIMENTAL
Intervention: Lack of sufficient religious contact
Number of subjects: 306
Study 28653458 — intervention group
Group type: EXPERIMENTAL
Intervention: LV-only pacing
Number of subjects: 161
Study 28653458 — intervention group
Group type: COMPARATOR
Intervention: Biventricular pacing
Number of subjects: 161
Study 25639289 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (2 times per week for 5 weeks, total of 10 sessions)
Number of subjects: 36
Study 25639289 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 36
Study 23303614 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal BMI group (BMI 20-25)
Number of subjects: 80
Study 23303614 — intervention group
Group type: COMPARATOR
Intervention: Overweight group (BMI > 25)
Number of subjects: 80
Study 23303614 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 20350135 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 577
Study 20350135 — intervention group
Group type: EXPERIMENTAL
Intervention: DRD2/ANKK1 genotype (TT vs CC)
Number of subjects: 577
Study 18304675 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin Aspart 0.08 IU/kg BW 30 min before meal
Number of subjects: 20
Study 18304675 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin Aspart 0.04 IU/kg BW 30 min before meal
Number of subjects: 20
Study 18304675 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin Aspart 0.04 IU/kg BW 15 min before meal
Number of subjects: 20
Study 18304675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 16006728 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic L-thyroxine treatment
Number of subjects: 33
Study 16006728 — intervention group
Group type: COMPARATOR
Intervention: Follow-up without treatment
Number of subjects: 33
Study 16006728 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 33
Study 12440503 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoset pellets
Number of subjects: 20
Study 12440503 — intervention group
Group type: COMPARATOR
Intervention: Control (defect left empty)
Number of subjects: 20
Study 10511942 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranilast 0.5% eyedrops, administered 4 times a day for 3 months
Number of subjects: 35
Study 10511942 — intervention group
Group type: COMPARATOR
Intervention: Placebo eyedrops, administered 4 times a day for 3 months
Number of subjects: 35
Study 8622101 — intervention group
Group type: EXPERIMENTAL
Intervention: Isepamicin 15 mg/kg once daily + ceftazidime 2g twice daily
Number of subjects: 177
Study 8622101 — intervention group
Group type: EXPERIMENTAL
Intervention: Isepamicin 8 mg/kg once daily + ceftazidime 1g twice daily
Number of subjects: 177
Study 8622101 — intervention group
Group type: COMPARATOR
Intervention: Amikacin 7.5 mg/kg twice daily + ceftazidime 2g twice daily
Number of subjects: 177
Study 8622101 — intervention group
Group type: COMPARATOR
Intervention: Amikacin 7.5 mg/kg twice daily + ceftazidime 1g twice daily
Number of subjects: 177
Study 8622101 — intervention group
Group type: EXPERIMENTAL
Intervention: Isepamicin
Number of subjects: 177
Study 8622101 — intervention group
Group type: COMPARATOR
Intervention: Isepamicin and Amikacin
Number of subjects: 177
Study 2290023 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral adjuvant (taurine) with HBV vaccine
Number of subjects: 86
Study 2290023 — intervention group
Group type: COMPARATOR
Intervention: HBV vaccine alone (no adjuvant)
Number of subjects: 86
Study 7299507 — intervention group
Group type: EXPERIMENTAL
Intervention: 525 mg of ferrous sulfate (105 mg elemental iron) and 500 mg ascorbic acid
Number of subjects: 196
Study 7299507 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study 29510372 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily fiber intake during an 18-month weight loss intervention
Number of subjects: 0
Study 29510372 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline fiber intake
Number of subjects: 0
Study 27325862 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cyclophosphamide and methotrexate maintenance (cyclophosphamide 50 mg/day orally continuously and methotrexate 2.5 mg twice/day orally on days 1 and 2 of every week for 1 year)
Number of subjects: 1086
Study 27325862 — intervention group
Group type: COMPARATOR
Intervention: No CM
Number of subjects: 1086
Study 27325862 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cyclophosphamide and methotrexate maintenance
Number of subjects: 1086
Study 24225325 — intervention group
Group type: EXPERIMENTAL
Intervention: NRP-e (nurse-led email reminder program)
Number of subjects: 198
Study 24225325 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual CVD prevention and educational program)
Number of subjects: 198
Study 22172000 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation funded group (provided funding for compression bandaging and medical footwear)
Number of subjects: 120
Study 22172000 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilayer bandaging (received by those with confirmed diagnosis, irrespective of group)
Number of subjects: 120
Study 22172000 — intervention group
Group type: COMPARATOR
Intervention: Evaluation funded group
Number of subjects: 120
Study 20860238 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral Internal Sphincterotomy (BIS) at 3 and 9 o'clock
Number of subjects: 211
Study 20860238 — intervention group
Group type: COMPARATOR
Intervention: Unilateral Internal Sphincterotomy (UIS) at 3 o'clock
Number of subjects: 211
Study 18296421 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year trastuzumab treatment
Number of subjects: 3401
Study 18296421 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 3401
Study 15756004 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 levels less than or equal to the median (4.80 pg/mL)
Number of subjects: 191
Study 15756004 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 levels above the median (4.80 pg/mL)
Number of subjects: 191
Study 15756004 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 levels at a cut point of 13.31 pg/mL
Number of subjects: 191
Study 14507747 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen fumarate 0.025% ophthalmic solution
Number of subjects: 519
Study 14507747 — intervention group
Group type: COMPARATOR
Intervention: Placebo (as vehicle)
Number of subjects: 519
Study 14507747 — intervention group
Group type: COMPARATOR
Intervention: Levocabastine hydrochloride 0.05% ophthalmic suspension
Number of subjects: 519
Study 10593380 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracytoplasmic sperm injection (ICSI)
Number of subjects: 139
Study 10593380 — intervention group
Group type: COMPARATOR
Intervention: Conventional IVF
Number of subjects: 139
Study 8944829 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterially administered losartan (100-3000 ng/kg/min)
Number of subjects: 24
Study 8944829 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally administered losartan (50 mg once daily for 5 days)
Number of subjects: 24
Study 1816842 — intervention group
Group type: EXPERIMENTAL
Intervention: Ni59‐65Cr26‐23Mo11‐9 mass per cent alloys
Number of subjects: 7
Study 1816842 — intervention group
Group type: COMPARATOR
Intervention: Ni74‐85Cr15‐13Mo5‐3 alloys
Number of subjects: 7
Study 7040006 — intervention group
Group type: COMPARATOR
Intervention: Bare sclera operation technique
Number of subjects: 40
Study 7040006 — intervention group
Group type: EXPERIMENTAL
Intervention: Sr 90 irradiation on the 1st, 7th and 14th postoperative day (maximum 3 X 1000 rad)
Number of subjects: 40
Study 31351240 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped Care Intervention (SCI)
Number of subjects: 907
Study 31351240 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Usual Care (eUCA)
Number of subjects: 907
Study 29049336 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised group exercise
Number of subjects: 175
Study 29049336 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual physical exercise
Number of subjects: 175
Study 29049336 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate level physical activity
Number of subjects: 175
Study 29049336 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased exercising days
Number of subjects: 175
Study 29049336 — intervention group
Group type: COMPARATOR
Intervention: Control group (treatment as usual)
Number of subjects: 175
Study 25688638 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcuminoids (1500 mg/day in 3 divided doses; n = 19)
Number of subjects: 40
Study 25688638 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo capsules (n = 21)
Number of subjects: 40
Study 25248764 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/salmeterol 250/50 μg
Number of subjects: 639
Study 25248764 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol 50 μg
Number of subjects: 639
Study 21640495 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation
Number of subjects: 540
Study 19070462 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological trials
Number of subjects: 165
Study 19070462 — intervention group
Group type: COMPARATOR
Intervention: Nonpharmacological trials
Number of subjects: 165
Study 19070462 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicentered trials
Number of subjects: 165
Study 19070462 — intervention group
Group type: COMPARATOR
Intervention: Single-site studies
Number of subjects: 165
Study 17202811 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramosetron (0.3 mg)
Number of subjects: 50
Study 17202811 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron (16 mg)
Number of subjects: 50
Study 16225693 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture + physiotherapy
Number of subjects: 465
Study 16225693 — intervention group
Group type: COMPARATOR
Intervention: TENS-placebo + physiotherapy
Number of subjects: 465
Study 12544718 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (calcium antagonist + beta-blocker)
Number of subjects: 0
Study 10523945 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary angioplasty (PTCA)
Number of subjects: 0
Study 10523945 — intervention group
Group type: COMPARATOR
Intervention: Intense medical therapy
Number of subjects: 0
Study 7568747 — intervention group
Group type: EXPERIMENTAL
Intervention: Floss Plus easy flosser
Number of subjects: 62
Study 7568747 — intervention group
Group type: COMPARATOR
Intervention: Hand-held floss
Number of subjects: 62
Study 2177357 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and vindesine (2 monthly cycles of initial chemotherapy)
Number of subjects: 81
Study 2177357 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and vindesine (maintenance chemotherapy: 2 cycles or 4 cycles)
Number of subjects: 81
Study 2177357 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and vindesine (initial chemotherapy)
Number of subjects: 81
Study 2177357 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and vindesine (in responding patients)
Number of subjects: 81
Study 7351151 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine sulphate (0.08 mg/kg) administered by inhalation, four times a day for seven days
Number of subjects: 24
Study 7351151 — intervention group
Group type: COMPARATOR
Intervention: Isoproterenol hydrochloride (2.5 mg) administered by inhalation, four times a day for seven days
Number of subjects: 24
Study 31831561 — intervention group
Group type: EXPERIMENTAL
Intervention: Guadecitabine 30 mg/m2 s.c. once-daily for 5 days and carboplatin (G+C)
Number of subjects: 100
Study 31831561 — intervention group
Group type: COMPARATOR
Intervention: Treatment of choice (TC; topotecan, pegylated liposomal doxorubicin, paclitaxel, or gemcitabine)
Number of subjects: 100
Study 31831561 — intervention group
Group type: EXPERIMENTAL
Intervention: Guadecitabine and carboplatin (G+C)
Number of subjects: 100
Study 31831561 — intervention group
Group type: COMPARATOR
Intervention: Treatment of choice (TC)
Number of subjects: 100
Study 31146679 — intervention group
Group type: EXPERIMENTAL
Intervention: LVPEG-4 (1 L preparation + 1 L required additional fluid)
Number of subjects: 120
Study 31146679 — intervention group
Group type: COMPARATOR
Intervention: Control (2 L PEG + Asc)
Number of subjects: 120
Study 27869451 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered family-based cognitive-behavioral therapy (FB-CBT)
Number of subjects: 22
Study 27869451 — intervention group
Group type: COMPARATOR
Intervention: Clinic-based family-based cognitive-behavioral therapy (FB-CBT)
Number of subjects: 22
Study 25567068 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 294
Study 25567068 — intervention group
Group type: COMPARATOR
Intervention: Antiarrhythmic drug therapy (AAD)
Number of subjects: 294
Study 25567068 — intervention group
Group type: EXPERIMENTAL
Intervention: Both AAD and RFA
Number of subjects: 294
Study 24363933 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin added to current medication
Number of subjects: 611
Study 24363933 — intervention group
Group type: COMPARATOR
Intervention: Current medications only (Control)
Number of subjects: 611
Study 21157387 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric (ISO) conditioning contraction
Number of subjects: 10
Study 21157387 — intervention group
Group type: COMPARATOR
Intervention: Concentric (CON) conditioning contraction
Number of subjects: 10
Study 21157387 — intervention group
Group type: COMPARATOR
Intervention: Eccentric (ECC) conditioning contraction
Number of subjects: 10
Study 21157387 — intervention group
Group type: COMPARATOR
Intervention: Concentric‐eccentric (DYN) conditioning contraction
Number of subjects: 10
Study 19520734 — intervention group
Group type: EXPERIMENTAL
Intervention: Locomotor training with therapist assistance
Number of subjects: 19
Study 19520734 — intervention group
Group type: COMPARATOR
Intervention: Robotic‐assisted locomotor training
Number of subjects: 19
Study 17712655 — intervention group
Group type: EXPERIMENTAL
Intervention: Removal of catheter and vaginal pack after 3 h
Number of subjects: 136
Study 17712655 — intervention group
Group type: COMPARATOR
Intervention: Removal of catheter and vaginal pack after 24 h
Number of subjects: 136
Study 15156431 — intervention group
Group type: EXPERIMENTAL
Intervention: Directly administered antiretroviral therapy (DAART)
Number of subjects: 0
Study 15156431 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 15156431 — intervention group
Group type: COMPARATOR
Intervention: Treatment-adherence support
Number of subjects: 0
Study 11270011 — intervention group
Group type: COMPARATOR
Intervention: Single injection technique with 20 mL of ropivacaine 0.75%
Number of subjects: 30
Study 11270011 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple injection technique with 20 mL of ropivacaine 0.75%
Number of subjects: 30
Study 11270011 — intervention group
Group type: COMPARATOR
Intervention: Single group
Number of subjects: 30
Study 11270011 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple group
Number of subjects: 30
Study 9727567 — intervention group
Group type: EXPERIMENTAL
Intervention: Saquinavir (SQV) in combination with zalcitabine (ddC) (with or without ZDV) for 1 year
Number of subjects: 169
Study 9727567 — intervention group
Group type: EXPERIMENTAL
Intervention: Saquinavir (SQV) plus zalcitabine (ddC)
Number of subjects: 169
Study 9727567 — intervention group
Group type: EXPERIMENTAL
Intervention: Saquinavir (SQV) treatment
Number of subjects: 169
Study 9727567 — intervention group
Group type: EXPERIMENTAL
Intervention: Saquinavir (SQV)
Number of subjects: 169
Study 8289855 — intervention group
Group type: EXPERIMENTAL
Intervention: Insurance coverage for ABMT
Number of subjects: 533
Study 8289855 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who underwent ABMT despite denial
Number of subjects: 533
Study 8289855 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who did not undergo ABMT
Number of subjects: 533
Study 8289855 — intervention group
Group type: EXPERIMENTAL
Intervention: Inconsistency in approval
Number of subjects: 533
Study 8289855 — intervention group
Group type: EXPERIMENTAL
Intervention: Predetermination process
Number of subjects: 533
Study 2637530 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet fluoridation
Number of subjects: 0
Study 2637530 — intervention group
Group type: COMPARATOR
Intervention: Complex preventive programmes
Number of subjects: 0
Study 15780704 — intervention group
Group type: EXPERIMENTAL
Intervention: venlafaxine XR (225 mg/day)
Number of subjects: 20
Study 15780704 — intervention group
Group type: COMPARATOR
Intervention: paroxetine (30 mg/day)
Number of subjects: 20
Study 31848757 — intervention group
Group type: EXPERIMENTAL
Intervention: Gasless BABA robotic thyroidectomy
Number of subjects: 28
Study 31848757 — intervention group
Group type: COMPARATOR
Intervention: Conventional BABA robotic thyroidectomy (CO2 group)
Number of subjects: 28
Study 31035478 — intervention group
Group type: EXPERIMENTAL
Intervention: 140 mL of concentrated beetroot juice (800 mg NO3‐)
Number of subjects: 15
Study 31035478 — intervention group
Group type: COMPARATOR
Intervention: Placebo (NO3‐‐depleted beetroot juice)
Number of subjects: 15
Study 27593398 — intervention group
Group type: EXPERIMENTAL
Intervention: Syntometrine
Number of subjects: 1200
Study 27593398 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin
Number of subjects: 1200
Study 25902705 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive anthelminthic treatment
Number of subjects: 26
Study 25902705 — intervention group
Group type: COMPARATOR
Intervention: Standard anthelminthic treatment
Number of subjects: 26
Study 24195204 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleeding and cupping therapy, applied locally with pricking and cupping once every two days for a total of 8 treatments.
Number of subjects: 64
Study 24195204 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin, 150mg orally, twice a day for a total of 16 days.
Number of subjects: 64
Study 21242217 — intervention group
Group type: EXPERIMENTAL
Intervention: High exposure to cigarette advertisements
Number of subjects: 2102
Study 21242217 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium exposure to cigarette advertisements
Number of subjects: 2102
Study 21242217 — intervention group
Group type: COMPARATOR
Intervention: Low exposure to cigarette advertisements
Number of subjects: 2102
Study 19091808 — intervention group
Group type: EXPERIMENTAL
Intervention: TREAT decision support system
Number of subjects: 161
Study 19091808 — intervention group
Group type: COMPARATOR
Intervention: Clinical practice (first attending clinical physician's treatment)
Number of subjects: 161
Study 16541783 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg x kg(‐1) LCT/MCT propofol
Number of subjects: 97
Study 16541783 — intervention group
Group type: COMPARATOR
Intervention: 0.2 mg x kg(‐1) LCT propofol
Number of subjects: 97
Study 16541783 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg x kg(‐1) LCT propofol
Number of subjects: 97
Study 16541783 — intervention group
Group type: COMPARATOR
Intervention: 0.4 mg x kg(‐1) LCT/MCT propofol
Number of subjects: 97
Study 15214587 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyhexamethylene biguanide (PHMB) vaginal gel, single-dose administration
Number of subjects: 110
Study 15214587 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin vaginal cream, 1 daily administration for 7 days
Number of subjects: 110
Study 10792202 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime 40 mg kg‐1 8 hourly by bolus injection
Number of subjects: 34
Study 10792202 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime 4 mg kg‐1 h‐1 by constant infusion following a 12 mg kg‐1 priming dose
Number of subjects: 34
Study 10792202 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime (both interventions)
Number of subjects: 34
Study 9186297 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolrestat treatment for 4 weeks in 17 patients
Number of subjects: 79
Study 9186297 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 4 weeks in 17 patients
Number of subjects: 79
Study 9186297 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood glucose control for 4 weeks in 7 patients
Number of subjects: 79
Study 9186297 — intervention group
Group type: COMPARATOR
Intervention: Normal controls (7 subjects) treated with tolrestat for 4 weeks
Number of subjects: 79
Study 8422517 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (any of the four regimens)
Number of subjects: 164
Study 8422517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study 8422517 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmenopausal women
Number of subjects: 164
Study 3525423 — intervention group
Group type: EXPERIMENTAL
Intervention: Viminol R2 10 mg
Number of subjects: 42
Study 3525423 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine 30 mg
Number of subjects: 42